Sanofi Contingent Value Rights
GCVRZ
GCVRZ was delisted on the 3rd of March, 2020.
106 hedge funds and large institutions have $76.1M invested in Sanofi Contingent Value Rights in 2018 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 11 increasing their positions, 16 reducing their positions, and 8 closing their positions.
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
19% more capital invested
Capital invested by funds: $64M → $76.1M (+$12.1M)
6% more funds holding
Funds holding: 100 → 106 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
31% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$304K |
| 2 |
SAM
Silverback Asset Management
Chapel Hill,
North Carolina
|
+$157K |
| 3 |
BRF
B. Riley Financial
Los Angeles,
California
|
+$114K |
| 4 |
CI
Cowen Inc
New York
|
+$17.7K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$13.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CL
CSS LLC
Chicago,
Illinois
|
-$71.2K |
| 2 |
PC
Pomelo Capital
New York
|
-$66.8K |
| 3 |
PC
Permanens Capital
New York
|
-$48K |
| 4 |
TL
TowerView LLC
New York
|
-$46.6K |
| 5 |
DBG
De Burlo Group
Boston,
Massachusetts
|
-$16K |
GCVRZ Hedge Fund Activity: Q2 2018 in Review
106 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q2 2018, worth a combined $76.1M — up 19% from $64M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new GCVRZ positions and 8 closed out — a net gain of 7 holders — while 11 added to existing stakes and 16 trimmed.
The largest buyer was Highbridge Capital Management, adding an estimated $304K. The largest seller was CSS LLC, cutting an estimated $71.2K.
- 106 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q2 2018, up from 100 in Q1 2018.
- Funds reported $76.1M of Sanofi Contingent Value Rights stock for Q2 2018, up 19% quarter-over-quarter.
- 15 funds opened new Sanofi Contingent Value Rights positions in Q2 2018 and 8 closed out, a net change of +7 holders.
- The largest Sanofi Contingent Value Rights buyer in Q2 2018 was Highbridge Capital Management, an estimated $304K added.
- The largest Sanofi Contingent Value Rights seller in Q2 2018 was CSS LLC, an estimated $71.2K sold.
Based on aggregated 13F filings for Q2 2018.